Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
4.000
-0.230 (-5.44%)
May 6, 2025, 11:26 AM EDT - Market open
Solid Biosciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Solid Biosciences stock have an average target of 15.67, with a low estimate of 11 and a high estimate of 20. The average target predicts an increase of 291.75% from the current stock price of 4.00.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 13, 2025.
Analyst Ratings
The average analyst rating for Solid Biosciences stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 4 | 3 |
| Buy | 6 | 8 | 8 | 8 | 8 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 12 | 12 | 12 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $12 → $11 | Buy | Maintains | $12 → $11 | +175.00% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $20 | Strong Buy | Maintains | $16 → $20 | +400.00% | Mar 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +300.00% | Mar 7, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $15 | Buy | Reiterates | $15 | +275.00% | Mar 7, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 → $16 | Strong Buy | Maintains | $15 → $16 | +300.00% | Feb 19, 2025 |
Financial Forecast
Revenue This Year
255.00K
Revenue Next Year
1.71M
from 255.00K
Increased by 569.02%
EPS This Year
-2.24
from -3.06
EPS Next Year
-2.40
from -2.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.2M | 19.3M | 134.4M | ||
| Avg | 255,000 | 1.7M | 29.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 7,476.5% | 7,778.1% | ||
| Avg | - | 569.0% | 1,627.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.63 | -1.30 | -1.27 | ||
| Avg | -2.24 | -2.40 | -2.29 | ||
| Low | -3.46 | -4.51 | -4.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.